drugset / Trial / NCT01632852
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
NaSingle-groupOpen-labelTreatment
Summary
This is a first in human, prospective, multicenter, nonrandomized, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of repeat doses of CSL362.
Timeline
- Start
- 2012-07
- Primary completion
- 2015-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talacotuzumab | Monoclonal antibody | 12 mg/kg | Intravenous |